NCCN Guidelines for Patients: Early-Stage Prostate Cancer, 2026 (2026)

Other · National Comprehensive Cancer Network (NCCN) · 2026

National Comprehensive Cancer Network (NCCN), 2026: The NCCN patient guide for early-stage (localized) prostate cancer describes surgery, radiation and active surveillance as the treatments; the 84-page document never mentions chemotherapy or docetaxel anywhere.

Common treatments for early-stage prostate cancer include surgery and radiation therapy, which are sometimes combined with hormone therapy. Or, your treatment plan may include no direct therapy but instead involve active surveillance or observation.

37

National Comprehensive Cancer Network (NCCN), 2026: The NCCN patient guide for early-stage (localized) prostate cancer describes surgery, radiation and active surveillance as the treatments; the 84-page document never mentions chemotherapy or docetaxel anywhere. Funder: NCCN (non-profit guideline body), funded by member institutions and guideline sales. Conflicts: NCCN panel disclosures not reproduced in the patient version. Maker: n/a. Comparator: n/a. Correction: full-text search of the PDF returns zero hits for 'chemo', 'docetaxel' or 'Taxotere' – the absence is the finding, not an omission in this record.